BioIntelliSense
Golden, US · Founded 2019 · Delaware corporation · 83 employees on LinkedIn · 4 known investors
Find your way into BioIntelliSense
Each arrow is one introduction. Sign up to fill in the first one.
Ask Kimberly Muller to introduce you to James Mault
You →Kimberly · together at BioIntelliSense →James
Ask Jamie Chen to introduce you to David Wang
You →Jamie · together at BioIntelliSense →David
Sign up to find every way you can get introduced to BioIntelliSense
- Your email: who you already know at BioIntelliSense, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the BioIntelliSense team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
BioIntelliSense develops scalable physiologic monitoring technology for continuous, proactive patient monitoring aimed at improving clinical outcomes and lowering the cost of care. Founded in 2019, the company builds medical monitoring solutions for healthcare providers and patients.
Founders & leadership
BioIntelliSense was founded in 2019 by James Mault.


Board
Investors · 4
Reported raises · per SEC filings
Form D private placements$140.3M disclosed across 4 rounds · 2018–2025
▶$58.3MraisedJun 2026 · 14 investors · OtherRule 506(b)
- Conlan MaDirector
- David WangExecutive Officer, Director
- Xinyaun YuDirector
- James MaultExecutive Officer, Director
- Offering amount
- $58.4M
- Amount sold
- $58.3M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$45MraisedSep 2022 · 16 investors · Other Health CareRule 506(b)
- David WangExecutive Officer
- Alan MeekerDirector
- James R. MaultExecutive Officer, Director
- John DriscollDirector
- Lawrence LeisureDirector
- Steve HessDirector
- Offering amount
- $45M
- Amount sold
- $45M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$25MraisedSep 2020 · 22 investors · Other Health CareRule 506(b)
- Steve HessDirector
- Alan MeekerDirector
- Larry LeisureDirector
- Ronald ChwangDirector
- James MaultExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$12MraisedSep 2020 · 11 investors · Other Health CareRule 506(b)
- James MaultExecutive Officer, Director
- Ronald ChwangDirector
- Alan MeekerDirector
- Larry LeisureDirector
- Steve HessDirector
- Offering amount
- $12M
- Amount sold
- $12M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Companies working in the same space as BioIntelliSense.
In the news
Frequently asked questions
- What does BioIntelliSense do?
- BioIntelliSense develops scalable physiologic monitoring technology for continuous, proactive patient monitoring aimed at improving clinical outcomes and lowering the cost of care. Founded in 2019, the company builds medical monitoring solutions for healthcare providers and patients.
- Who founded BioIntelliSense?
- BioIntelliSense was founded by James Mault in 2019.
- Who are BioIntelliSense's investors?
- BioIntelliSense's investors include Bose Ventures, CU Healthcare Innovation Fund, Fresenius Medical Care Ventures, SkyPoint Ventures.
- How much funding has BioIntelliSense raised?
- BioIntelliSense has disclosed $140.3M raised across 4 rounds.
- Where is BioIntelliSense headquartered?
- BioIntelliSense is headquartered in Golden, US.








